Yong Ben's most recent trade in BridgeBio Oncology Therapeutics Inc. was a trade of 357,177 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Aug. 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BridgeBio Oncology Therape... | Yong Ben | Chief Med & Dev Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2025 | 357,177 | 357,177 | - | - | Stock Option (Right to Buy) | |
| Corbus Pharmaceuticals | Yong Ben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2025 | 16,000 | 16,000 | - | - | Stock options (right to buy) | |
| Corbus Pharmaceuticals | Yong Ben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2025 | 4,800 | 7,583 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| Corbus Pharmaceuticals | Yong Ben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 2,783 | 2,783 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| Corbus Pharmaceuticals | Yong Ben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 2,783 | 2,783 | - | - | Stock Option (right to buy) | |
| Corbus Pharmaceuticals | Yong Ben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 5,300 | 5,300 | - | - | Stock Option (right to buy) | |
| Corbus Pharmaceuticals | Yong Ben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 5,307 | 5,307 | - | - | Stock Option(right to buy) |